208 related articles for article (PubMed ID: 19196156)
1. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain.
Stern L; Perry R; Ofek P; Many A; Shabat D; Satchi-Fainaro R
Bioconjug Chem; 2009 Mar; 20(3):500-10. PubMed ID: 19196156
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.
Liu C; Sun C; Huang H; Janda K; Edgington T
Cancer Res; 2003 Jun; 63(11):2957-64. PubMed ID: 12782603
[TBL] [Abstract][Full Text] [Related]
4. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
[TBL] [Abstract][Full Text] [Related]
7. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
8. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
10. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
[TBL] [Abstract][Full Text] [Related]
11. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
12. Suicide gene therapy using E. coli beta-galactosidase.
Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
[TBL] [Abstract][Full Text] [Related]
13. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design.
Zhang M; Jiang Z; Chen S; Wu Z; Chen K; Wu Y
Chem Biol Drug Des; 2018 Feb; 91(2):534-544. PubMed ID: 28994241
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
Chuang KH; Cheng CM; Roffler SR; Lu YL; Lin SR; Wang JY; Tzou WS; Su YC; Chen BM; Cheng TL
Bioconjug Chem; 2006; 17(3):707-14. PubMed ID: 16704208
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Prodrug Conjugates with KSP Inhibitors and Legumain-Mediated Metabolite Formation.
Lerchen HG; Stelte-Ludwig B; Berndt S; Sommer A; Dietz L; Rebstock AS; Johannes S; Marx L; Jörißen H; Mahlert C; Greven S
Chemistry; 2019 Jun; 25(35):8208-8213. PubMed ID: 30869180
[TBL] [Abstract][Full Text] [Related]
16. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
17. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
Liu Y; Bajjuri KM; Liu C; Sinha SC
Mol Pharm; 2012 Jan; 9(1):168-75. PubMed ID: 22044266
[TBL] [Abstract][Full Text] [Related]
18. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
